Spectra Optia for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology Guidance by unknown
REVIEW ARTICLE
Spectra Optia for Automated Red Blood Cell Exchange
in Patients with Sickle Cell Disease: A NICE Medical Technology
Guidance
Iain Willits1,4 • Helen Cole1 • Roseanne Jones1 • Kimberley Carter2 •
Mick Arber3 • Michelle Jenks3 • Joyce Craig3 • Andrew Sims1
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract The Spectra Optia automated apheresis system,
indicated for red blood cell exchange in people with sickle
cell disease, underwent evaluation by the National Institute
for Health and Care Excellence, which uses its Medical
Technologies Advisory Committee to make recommenda-
tions. The company (Terumo Medical Corporation) pro-
duced a submission making a case for adoption of its
technology, which was critiqued by the Newcastle and
York external assessment centre. Thirty retrospective
observational studies were identified in their clinical sub-
mission. The external assessment centre considered these
were of low methodological and reporting quality. Most
were single-armed studies, with only six studies providing
comparative data. The available data showed that, com-
pared with manual red blood cell exchange, Spectra Optia
reduces the frequency of exchange procedures as well as
their duration, but increases the requirement for donor
blood. However, other clinical and patient benefits were
equivocal because of an absence of robust clinical evi-
dence. The company provided a de novo model to support
the economic proposition of the technology, and reported
that in most scenarios Spectra Optia was cost saving, pri-
marily through reduced requirement of chelation therapy to
manage iron overload. The external assessment centre
considered that although the cost-saving potential of
Spectra Optia was plausible, the model and its clinical
inputs were not sufficiently robust to demonstrate this.
However, taking the evidence together with expert and
patient advice, the Medical Technologies Advisory Com-
mittee considered Spectra Optia was likely to save costs,
provide important patient benefits, and reduce inequality,
and gave the technology a positive recommendation in
Medical Technology Guidance 28.
Key Points for Decision Makers
The Spectra Optia apheresis system provides
automated red blood cell exchange for people with
chronic symptomatic sickle cell disease. It is
operationally more efficient than manual red blood
cell exchange, resulting in improved clinical and
patient outcomes and improved regulation of iron
levels.
The paucity of clinical evidence to support the
Spectra Optia system largely reflects a lack of
clinical equipoise. Limited observational evidence
and expert opinion suggest the system provides long-
term savings to the National Health Service,
primarily through a reduction in the requirement for
iron chelation therapy.
With the correct service provision, the Spectra Optia
system could also reduce geographical inequalities in
the management of sickle cell disease.
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1 Introduction
The National Institute for Health and Care Excellence
(NICE) provides evidence-based guidance for the National
Health Service (NHS) in England and Wales with the aim
of improving clinical outcomes for patients as well as
delivering optimal use of finite NHS resources. The NICE
Medical Technologies Evaluation Programme (MTEP) was
established in 2009 and, together with the independent
Medical Technologies Advisory Committee (MTAC), is
responsible for the evaluation of medical technologies
(interventions or diagnostics) for use within the NHS [1].
To be selected for evaluation, a technology must hold a
current CE (conformite´ Europe´enne) mark or be expected
to gain one within 12 months, and must be considered by
the MTAC to have ‘plausible promise’ [2]. To be recom-
mended for adoption, a technology must demonstrate
equivalent benefit to patients at lower cost to the NHS, or
greater benefit with equivalent costs. Once selected by the
MTAC and assessment is commenced, the medical tech-
nology will usually undergo a relatively rapid guidance
development process of 38 weeks. It is the responsibility of
the company (that is, the manufacturer or UK distributor of
the technology) to produce a submission whereby the
claimed benefits of the technology to the patient and/or
NHS must be demonstrated. The company’s submission is
evaluated by an external assessment centre (EAC), which
has the responsibility of critically assessing the clinical and
cost evidence in the company’s submission, and its rele-
vance to the decision problem defined in the evaluation
scope. Finally, recommendations for adoption are made by
the MTAC, who consider the evidence presented by the
company and the EAC, with assistance from clinical
experts and, sometimes, patient representatives. This pro-
cess is facilitated from start to finish by the MTEP [3].
The Spectra Optia automated apheresis system, manu-
factured and supplied by Terumo Medical Corporation, was
granted a CEmark as a class IIbmedical device inMay 2014.
It has several applications relating to the in situ separation of
blood components, including automated red blood cell
(RBC) exchange or depletion exchange in adults or children
with sickle cell disease. Following selection of the technol-
ogy in April 2015, assessment began in June 2015, with the
clinical and economic evaluation conducted by the New-
castle and York EAC (Newcastle upon Tyne Hospitals NHS
Foundation Trust and York Health Economics Consortium
partnership). In March 2016, NICE issued final guidance on
‘‘SpectraOptia for automatedRBCexchange in patientswith
sickle cell disease’’. Full documentation of the process,
supporting evidence and the final guidance is available on the
NICE website [4], including the company submission [5],
and the EAC’s assessment report [6]. This article provides an
overview of the company’s submission of evidence, the
EAC’s critique of the evidence, and the formulation of final
guidance. It is one of a series of NICE Medical Technology
Guidance (MTG) summaries being published in Applied
Health Economics and Health Policy.
2 Background to the Condition and Technology
Sickle cell disease is a group of recessive genetic blood
disorders in people who have inherited two copies of a
mutated gene for haemoglobin production. The most
common variant of the disease, occurring when two copies
of the sickle cell gene are present (HbSS), is sickle cell
anaemia, although other significant variants also occur,
such as b-thalassaemia [7]. Sickle cell disease manifests as
an abnormality in the haemoglobin molecule, which causes
the RBCs to become rigid and deform into the eponymous
sickle-like shape, with two important consequences. First,
sickled cells undergo haemolysis, resulting in them having
a much shorter half-life than normal RBCs (typically
10–20 days compared with 90–120 days), which can lead
to severe and life-threatening anaemia. Second, the sickled
deformity causes damage to blood vessels. Large vessel
damage is caused by repeated endothelial damage by
adherent sickle cells, complicated by vasoconstriction and
nitric oxide deficiency, and leads to complications such as
stroke, acute chest syndrome, and priapism. Small vessel
occlusion is caused directly by sickled cells and is asso-
ciated with acute episodes such as a painful crisis or more
chronic damage such as avascular necrosis of the hips and
renal failure. An additional complication of sickle cell
disease is growth impairment in children [7].
An example of a clinical pathway for the management
of sickle cell disease is summarised in Fig. 1. For most
people, the first-line treatment for chronic, symptomatic
sickle cell disease is the anti-neoplastic drug hydroxycar-
bamide, which stimulates the production of foetal hae-
moglobin in the blood (which does not cause sickle
formation). However, approximately 25% of patients are
unable or unwilling to take hydroxycarbamide (because of
contraindications or because they cannot tolerate it) or
remain refractory to treatment. Pregnant or breastfeeding
women, or people of both sexes planning to conceive,
should not take hydroxycarbamide [8]. Additionally,
hydroxycarbamide is not indicated as a preventative mea-
sure in patients who are at a very high risk of stroke.
For patients in whom hydroxycarbamide is not suitable,
or for patients requiring primary or secondary prevention
of stroke, an elective blood transfusion may be indicated.
Options include simple top-up transfusion, RBC manual
exchange transfusion, and automated RBC exchange
transfusion. The initial choice of transfusion therapy
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depends on a range of factors dependent on clinical status
and, in practice, local facilities.
A top-up transfusion consists of the simple transfusion
of donor blood into the recipient. In general, top-up
transfusions are suitable if the main purpose of treatment is
to manage anaemia, and the introduction of transfusions
does not pose an unacceptable increase in the risk of vaso-
occlusive events, such as stroke. However, top-up trans-
fusions are ‘iron positive’, and are associated with an
unavoidable accumulation of iron in the body. Iron
overload, which is characterised by an attendant increase in
serum ferritin, can cause serious complications such as
liver cirrhosis, heart failure, and diabetes mellitus [9].
Thus, the use of top-up transfusions will inevitably require
iron chelation therapy, typically after around 20 transfu-
sions. Iron chelation therapy is often poorly tolerated by
patients, has consequent issues with non-compliance, and is
expensive.
The alternative to simple top-up transfusion is RBC
exchange transfusion in which blood is removed through
Fig. 1 Flow chart illustrating patient pathways for people with chronic sickle cell disease. Produced with information from Howell et al. [17],
the Sickle Cell Society [7] and clinical experts. Hb haemoglobin, RBC red blood cell
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venesection and replaced with an equal volume of donor
blood. Manual exchange is the simplest method, and has
the advantage of being versatile by virtue of not requiring
specialist technology to be implemented [10]. In automated
RBC exchange, an apheresis machine removes patient
blood and extracts the RBCs through centrifugation. The
non-RBC component of the blood (principally plasma and
white cells), supplemented with packed donor RBC units
(or, in the case of depletion exchange, an isomolar solution
such as normal saline), is simultaneously returned to the
patient through a second line. Both manual and automated
RBC exchanges are considered to be ‘iron neutral’ because
packed RBCs are used to replace the patient’s blood in an
isovolaemic manner. However, in practice, owing to
technical and practical limitations, manual exchange tends
to lead to iron accumulation and its associated complica-
tions. In contrast, automated RBC exchange is thought to
be truly iron neutral and its use is believed to avoid the
need for chelation therapy [11].
The Spectra Optia device is an automated apheresis
system that is indicated for the elective treatment of sickle
cell disease (as well as for other indications such as plasma
exchange and stem cell harvesting). In their submission to
NICE, the claimed benefits for patients made by the
company were as follows: reduced frequency of exchange;
reduced duration of exchange; reduced iron overload,
meaning a reduction or possible cessation of chelation
therapy; and better compliance and efficiency resulting in
improved clinical outcomes, such as a reduced incidence of
stroke, painful crises, acute chest syndrome, improved
outcomes following surgery, improved growth in children,
and improved quality of life. Claimed benefits for the
healthcare system were a reduction in the requirement for
iron chelation therapy; reduced staff and staff grade;
reduced complications (and consequent reduction in hos-
pital admissions); and improved use of donor blood
(through the depletion-exchange protocol) [12].
3 Decision Problem (Scope)
In their submission to NICE for assessment, companies are
required to define and adhere to a decision problem, which
is described in PICO (population, intervention, comparator,
outcomes) terms and is consistent with the published scope
of the MTG [12]. The EAC uses this as a reference during
its critique of the submission.
3.1 Population
The population described by the company in the decision
problem was ‘‘Sickle cell disease patients requiring a
medium or long-term transfusion regime’’. It was noted by
the EAC that this represented a subtle, but important
change from the scope that specified the requirement for
exchange transfusion regime (see Sect. 3.3) [12]. The EAC
also considered that the proposed addition of management
of acute complications of sickle cell disease, which is the
subject of a NICE clinical guideline [13], was outside the
scope.
3.2 Intervention
The intervention in the MTEP scope was the ‘‘Spectra
Optia apheresis device’’ [12]. In the decision problem, the
company had modified this to include the ‘‘Cobe Spectra
apheresis device’’, the predecessor technology to the
Spectra Optia device, to increase the size of the evaluable
evidence base, as there was a paucity of evidence published
on the Spectra Optia device itself. The company stated that
the Spectra Optia and Cobe Spectra were ‘‘essentially
equivalent devices’’, and reported three head-to-head
clinical studies to support this assertion [14–16]. However,
following discussion with company representatives and
clinical experts, the EAC was satisfied that the Spectra
Optia system was likely to be technically equivalent, or
superior to, the Cobe Spectra system. This was because the
Spectra Optia system represents an incremental improve-
ment, rather than a fundamental change, over the older
Cobe Spectra system. The additional functionality built
into the system has the potential to improve safety, oper-
ator performance, and patient experience, and has impli-
cations for resource use, but should not negatively impact
on the system’s efficacy compared with the Cobe Spectra
system. Therefore, the EAC considered that it was rea-
sonable to generalise evidence reported on the Cobe
Spectra system to the Spectra Optia system.
3.3 Comparator
The comparator listed in the scope was ‘‘Manual red blood
cell exchange’’ [12]. In their statement of the decision
problem, the company proposed ‘‘Simple or ‘top up’
transfusions’’ as an additional comparator. This was justi-
fied by the company on the basis that the use of top-up
transfusions reflects current NHS practice. Whilst recog-
nising the reality that administering top-up transfusions
(usually combined with iron chelation therapy) was a
strategy that was practised in some NHS regions, the EAC
disagreed that was a satisfactory reason to consider it as a
valid comparator. This was because a top-up transfusion is
mechanistically different to exchange transfusion and is
known to be a suboptimal option for most patients, as
although it effectively treats anaemia, it is less effective at
preventing vaso-occlusive complications as it increases
blood viscosity [7, 17]. Top-up transfusions have different
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indications and contraindications and different targets
compared with exchange transfusions and are relatively
contraindicated where iron overload is liable to be prob-
lematic [17] (which is inevitable when frequent elective
top-up transfusions are performed).
3.4 Outcomes
The company’s reporting of the outcomes of the decision
problem matched the scope [12], with the proposal of
alloimmunisation as an additional safety outcome, which
the EAC agreed should be considered. The outcomes
specified in the scope were categorised as primary or sec-
ondary, and consisted of a mixture of intermediate, clinical,
patient benefit, adverse events, and resource use endpoints.
One outcome, the proportion of total haemoglobin that
is sickled (HbS%), is an intermediate or surrogate measure
of disease severity and risk of vaso-occlusive complica-
tions, which fluctuates during treatment cycles. Usually,
the target HbS% should be kept under 30% [7]. Patient
haematocrit (an indicator for anaemia and target during
RBC exchange transfusion), iron overload, and the asso-
ciated need for chelation therapy were also listed as end-
points, although the latter was not clearly defined.
‘‘Clinical outcomes including frequency of stroke,
multi-organ failure, acute chest syndrome and pain crises’’
was the main clinical endpoint listed, with body mass index
and growth in children listed as secondary outcomes.
Quality of life was the only outcome directly related to
patient benefit. Several resource use outcomes were
included in the decision problem, including duration of
exchange procedure; frequency of treatment; length of
hospital stay; and staff time and staff group/grade.
The company identified published evidence on most of
these outcomes with the exception of staff time and staff
group/grade, quality of life, and body mass index and
growth in children, and, importantly, clinical outcomes.
The company did not attempt to extrapolate intermediate
endpoints to clinical outcomes.
4 Review of Clinical Effectiveness Evidence
4.1 Company’s Review of Clinical Effectiveness
Evidence
The company performed a literature search and sift using
inclusion and exclusion criteria consistent with the original
scope [12]. Additional studies were found by searching
proceedings of annual conferences known to be relevant.
Studies were also included that compared RBC exchange
with top-up transfusions; the searching methodology of
these studies was not described causing the potential for
bias. In total, 30 studies were reported in the company
submission.
Six studies compared the Spectra Optia system, or its
predecessor the Cobe Spectra system, with manual RBC
exchange [18–23]. These were all retrospective observa-
tional studies that did not use an experimental comparative
design; three used historical controls [18, 21, 23], one was
a before-and-after study [19] and two were between-centres
studies [20, 22]. Only two of the studies were peer
reviewed [18, 20], one was a published letter [22], and
three were reported as conference abstracts [19, 21, 23].
Of the other 24 studies, 14 were single-armed studies
that reported absolute or ‘before and after data’, with seven
published as full peer-reviewed studies [24–30] and seven
as conference abstracts [31–37]. Two were single-armed
studies on manual exchange, both published as conference
abstracts [38, 39]. Three studies compared technical
aspects of the Spectra Optia and Cobe Spectra systems
[14–16], and four studies compared automated RBC
exchange with top-up transfusions [40–43]. One study was
in pregnant women [44].
The company interpreted the clinical evidence as
demonstrating that Spectra Optia resulted in shorter pro-
cedure times, longer intervals between procedures, and an
increased use of packed RBCs compared with manual
exchange. In addition, it reported that automated RBC
exchange was superior to manual RBC exchange at
reducing ferritin levels, and that there was general equiv-
alence with regard to the physiological parameters of
HbS% and haematocrit.
4.2 EAC Critique of Clinical Effectiveness Evidence
The EAC reproduced the company’s bibliographic data-
base searches, using the details as reported in the submis-
sion. Searches were not carried out for the company search
activities where insufficient information was provided to
enable replication. As far as possible, the bibliographic
database searches were replicated exactly as reported. The
EAC also conducted its own searches to retrieve any
studies that might have been missed by the company’s
search strategies, and sifted these according to the scope.
Results were reported using PRISMA methodology (Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses) [45] (Fig. 2). This identified four additional
studies [46–49], but these were conference abstracts that
did not help in answering the decision problem. Thus, the
EAC was confident that all relevant studies were included
in the submission of clinical evidence.
In the opinion of the EAC, the company critically
appraised the identified studies fairly and presented the
results in a tabular format. However, although the company
described many of the limitations of individual studies, it
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did not fully describe how this uncertainty might affect
confidence in the overall results. The company was correct
in not attempting data synthesis (meta-analysis) owing to
the heterogeneous nature of the studies; instead it presented
the results of each study in a tabular format and matched
individual study results against the outcomes and benefits
listed in the scope [12]. The company combined results
from single-armed and comparative studies in its inter-
pretation, which led to a greater volume of data on the
intervention (automated RBC exchange) compared with
the comparator (manual RBC exchange).
The majority of the evidence was from retrospective
observational studies, which were subject to potential
confounding, selection bias and reporting bias. Most of the
studies were single armed and not designed to directly
compare the intervention with the comparator, and the
heterogeneous nature of the studies did not allow for
meaningful data synthesis. The EAC noted that the quality
of reporting was often poor. Only a minority of the studies
were reported as full articles in peer-reviewed journals
[18, 20, 24, 26–29, 35, 44]. Details of the other unpub-
lished studies can be found in the EAC’s assessment report
[6].
The EAC focussed on results from the six comparative
studies with manual RBC exchange [18–23] because these
provided the most useful data relevant to the decision
problem, and the peer-reviewed single-armed studies of the
Spectra Optia [28] and Cobe Spectra systems
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[24, 26, 27, 29, 30], as these studies were fully reported and
provided useful supporting data. Details of these studies are
summarised in Table 1.
The EAC considered that these studies provided strong
evidence that, compared with manual RBC exchange, the
Spectra Optia system was associated with a shorter dura-
tion of procedure (about half the time), a reduced fre-
quency of treatments (2–3 weeks greater treatment
interval), and with an increased use of packed RBCs (ap-
proximately double for Spectra Optia). The EAC consid-
ered that the evidence on achieving HbS% and haematocrit
targets was equivocal, that is, the studies did not show that
Spectra Optia was different compared with manual RBC
exchange for these outcomes. The EAC considered that,
whilst the studies indicated that automated RBC exchange
was associated with a decrease or stabilisation in serum
ferritin levels compared with manual RBC exchange, this
effect had not been demonstrated statistically and the
overall implication on iron overload and the chelation
therapy requirement remained uncertain. There was no
comparative evidence reported on hospital admissions.
There was no meaningful comparative evidence reported
on staff resources, ease of venous access, quality of life,
and body mass index growth in children. Finally, there was
no evidence presented to support the comparative benefit of
the Spectra Optia system on clinical and complication
outcomes, such as stroke, painful crises, and acute chest
syndrome, and no studies provided results according to iron
overload status. A summary of how the results from the
identified clinical evidence addressed the outcomes speci-
fied in the decision problem and the claimed benefits is
reported in Table 2.
Owing to the lack of high- or moderate-quality obser-
vational evidence on key outcomes reported in the pub-
lished literature, the EAC communicated extensively with
clinical experts who were experienced with the use of
exchange transfusions. The EAC received qualitative
feedback from six of eight clinical experts approached,
who provided valuable information on the relative advan-
tages and disadvantages of the transfusion methods under
assessment. The experts were consistent in their opinions
that automated RBC exchange is more effective than
manual RBC exchange in reducing or maintaining ferritin
levels, and had the potential to avoid the need for initiating,
or allow for the cessation of, iron chelation therapy. When
questioned why there was a lack of good-quality prospec-
tive studies published to compare the efficacy and safety of
automated compared with manual RBC exchange, the
experts cited the relative rarity of the disease (especially
the subset of severe disease requiring chronic exchange
transfusion), the lack of competitor products, and a general
lack of funding from industry and charities to fund
experimental studies as reasons. The experts were
unanimous that future prospective experimental studies are
unlikely because of issues with clinical equipoise; that is, it
would be unethical to conduct trials as there is no clinical
doubt that automated RBC exchange is at least as effective
as manual RBC exchange, but it also offers clear additional
patient benefits. The full communication log with the
clinical experts is published during public consultation,
along with all of the relevant evidence supporting the
committee’s provisional recommendations [50].
5 Economic Evidence
5.1 Company’s Economic Submission
The company identified seven studies using the Cobe
Spectra or Spectra Optia systems that included economic
information [19, 26, 27, 29, 38, 40, 41]. However, these
studies were deemed by the company to be unhelpful
because they were poorly reported and were not robust;
therefore, they were not considered further.
The company developed a de novo economic model to
estimate the procedural and clinical costs associated with 5
years management of chronic, severe sickle cell disease
using automated RBC exchange (the Spectra Optia sys-
tem), manual RBC exchange, or top-up transfusions. The
model described 12 scenarios with starting populations
with different baseline characteristics (adults, children
requiring secondary prevention of stroke, or children
requiring primary prevention of stroke) and iron overload
severities (none, mild, moderate, or severe). As the relative
proportions of each population subgroup were not reported,
this meant that an overall ‘average’ cost of management
per person with sickle cell disease or overall budgetary
impact was not calculated.
The company reported that, in the base case, Spectra
Optia was always cost saving compared with manual RBC
exchange, with savings ranging from £360 to £52,516 per
patient over 5 years. In half of the scenarios (6/12), top-up
transfusion was cost saving compared with automated RBC
exchange (in adult or child patients with no or mild over-
load). Spectra Optia was associated with a greater
requirement for packed RBC units than its comparators.
For top-up transfusions, chelation therapy was the most
important cost. Manual RBC exchange was associated with
both relatively high procedural costs (through staffing
requirements) and chelation therapy costs, and was there-
fore the most expensive option. The company conducted
extensive univariate sensitivity analyses and threshold
analyses on each scenario presented in the model. These
were mainly based on adjusting healthcare resources and
unit costs, and in general the results of the analyses
favoured Spectra Optia.
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5.2 Critique of Economic Evidence
The EAC agreed with the company that the seven identified
studies in this assessment [19, 26, 27, 29, 38, 40, 41] were
not of sufficient methodological quality or relevance to
inform the decision problem. The EAC did not identify any
further economic studies using its own literature search.
The EAC considered that the de novo model had several
shortcomings. First, the model incorporated estimates of
rates from clinical events which, in the opinion of the EAC,
were not well supported by the evidence identified from the
clinical literature. Second, capital costs and maintenance
costs of the Spectra Optia device were not included in the
base-case results. Third, the inclusion of 12 subgroups,
which were not defined in the literature or recognised by
clinical experts, required the company to make assump-
tions on how the modalities would perform without clinical
evidence at that level of granularity. The EAC considered
the sensitivity analyses performed by the company were of
limited value because they did not challenge the underlying
assumptions of the model or address its limitations.
The EAC undertook an additional economic analysis
using the company’s model but adding the costs of the
technology, as well as including revised figures for key
resource use (primarily iron chelation therapy costs). The
analysis suggested that, compared with manual RBC
exchange, the Spectra Optia system was likely to be cost
saving in patients with no or mild iron overload, but cost
incurring in patients with moderate or severe iron overload
(see Table 3). This analysis was subject to the same
uncertainties as the company’s model.
In the opinion of the EAC, the cost-saving potential of the
Spectra Optia system, compared with manual exchange, had
not been demonstrated with confidence by the company’s
model. However, following correspondence with clinical
experts, theEACconsidered that the SpectraOptia systemhad
several economic benefits which, taken as whole, may be
resource saving for the NHS. These included reduced proce-
dure times and intervals between procedures; reduced need for
chelation therapy tomanage ironoverload; reducedvariability
in clinical practice, helping to standardise local and national
level practice; and improved safety and auditing of exchange
procedures. Additionally, the initial capital cost of the Spectra
Optia system could be offset by its use in other indications
such as plasma exchange apheresis and stem cell harvesting.
6 NICE Guidance
6.1 Provisional Recommendations and Consultation
In October 2015, the MTAC convened to make provisional
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the assistance of the EAC, three clinical expert advisors,
and a patient representative. The committee considered that
the available evidence indicated that automated RBC
exchange procedures are shorter and have a longer-lasting
clinical benefit than manual exchange, meaning that
patients need the procedure less often. However, the pub-
lished clinical evidence base to support other benefits of the
Spectra Optia system was generally poor and, in the
absence of robust published data, the committee accepted
the opinion of the experts that the Spectra Optia system
was the only reliable iron neutral transfusion treatment
available. This was because, in contrast to automated RBC
exchange, manual RBC exchange in a typical hospital
setting could not achieve the level of precision needed to
achieve absolute iron neutrality. Furthermore, the use of
chelation therapy to reduce iron overload is poorly toler-
ated by patients, which causes compliance issues, as well
as being expensive.
The committee further discussed issues concerning NHS
resources and costs. There is currently a lack of equity in
service provision in the treatment of sickle cell disease,
with people living outside large cities receiving suboptimal
treatment or facing significant transport issues. The cause
of provision inequity is related to the uneven geographical
distribution of people with sickle cell disease (prevalence)
and the consequent lack of availability of specialist
expertise and equipment in peripheral centres. Moreover,
current levels of NHS tariff remuneration are likely to act
as a disincentive to providers to adopt automated RBC
exchange.
Regarding costs, the MTAC recognised that the com-
pany’s economic model employed subgroups that were not
defined in practice, and that many of the inputs into the
economic model were based on unsubstantiated estimates
rather than empirical data. The committee heard that top-up
transfusions, whilst being recognised as a suboptimal reg-
imen, were used in practice in centres that had poor sickle
cell disease treatment provision and should be considered
in the analysis. Overall, the committee considered that,
despite the limitations of the clinical evidence and subse-
quent uncertainties this caused in the economic analysis,
the Spectra Optia system was likely to result in cost savings
for the NHS, especially when the technology was used
additionally for other indications. These cost savings would
mainly result from the reduced requirement of iron chela-
tion therapy.
Following the meeting, draft guidance was produced and
released for public consultation between 13 October and 10
November, 2015. In total, 48 comments were submitted by
external stakeholders. These were individually addressed
during the MTAC meeting held on 17 December, 2015.
The comments were mainly related to small factual inac-
curacies or a lack of clarity in the draft guidance and were
addressed by the MTEP. No important changes to the draft
recommendations were made following consultation.
6.2 Final NICE Guidance
In March 2016, NICE made the following recommenda-
tions concerning the use of the Spectra Optia system in the
management of people with chronic sickle cell disease [4]:
1.1 The case for adopting Spectra Optia for automated
RBC exchange in patients with sickle cell disease is
supported by the evidence. Spectra Optia is faster to
use and needs to be done less often than manual RBC
exchange.
1.2 Spectra Optia should be considered for automated
RBC exchange in patients with sickle cell disease
who need regular transfusion.
1.3 NICE recommends collaborative data collection to
generate further clinical evidence on some outcomes
of treatment with Spectra Optia. In particular, there is
a need for long-term data on how automated and
manual exchanges affect iron overload status and the
subsequent need for chelation therapy.
1.4 Based on current evidence and expert advice on the
anticipated benefits of the technology when used in
patients with iron overload, cost modelling shows that
in most cases using Spectra Optia is cost saving
compared with manual RBC exchange or top-up
transfusion. The savings depend on the iron overload
status of the patient, and are more likely to be
achieved if devices already owned by the NHS can be
used to treat sickle cell disease. The estimated cost
saving for adopting Spectra Optia is £18,100 per
patient per year, which has the potential to save the
NHS in England £12.9 million each year.
Recommendation 1.4 was based on additional work
performed by the NICE adoption and impact team [51].
7 Key Challenges and Learning Points
The Spectra Optia system ultimately received a positive
recommendation in the published guidance (MTG 28) [4].
During its evaluation of the technology, the EAC faced
several challenges, as did the MTAC during their deliber-
ation of guidance recommendations. As is often observed
with medical devices [52], there was a paucity of high-
quality clinical evidence, particularly from comparative
trials, for the EAC to assess the efficacy of Spectra Optia
and for the company to provide support for its claims. An
additional, and also familiar challenge, was the assessment
of evidence on multiple versions of the device [52]. In the
case of Spectra Optia, the absence of prospective
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comparative evidence could be ascribed to a lack of clin-
ical equipoise, which also means that there is little prospect
of a randomised controlled trial to directly address the
decision problem. The EAC were therefore heavily reliant
on the opinion of clinical experts to establish the efficacy of
the device. However, although experts were able to provide
qualitative evidence in support of Spectra Optia, they were
unable to provide the quantitative evidence necessary to
adequately inform the economic evidence, thus there
remains a large degree of uncertainty concerning the cost-
saving potential of the technology. This led the MTAC to
recommend the future collection of data, particularly on
iron overload status, to address this uncertainty [4].
Although it has been modelled that the Spectra Optia
device would lead to cost savings for the NHS as a whole
in the longer term (primarily through reduced iron chela-
tion therapy requirements), there are barriers to imple-
mentation resulting from reimbursement that must be
overcome for these to be realised. As the MTAC recog-
nised, a potential problem is that, at present, the tariff
reimbursement for plasma exchange is several times
greater than it is for RBC exchange [53], which incen-
tivises providers to use Spectra Optia for the former.
Another barrier is that whilst hospital trusts would be
required to provide the initial capital outlay for Spectra
Optia, they would not directly recoup most this money
from the expected reduction in iron overload, as chelation
drugs are currently provided by clinical commissioning
groups.
As acknowledged by the MTAC, currently, there is a
high level of geographical inequity with the provision of
automated RBC exchange, with services being absent
outside of major cities, and patients from these areas
having the prospect of suboptimal treatment or facing the
inconvenience and cost of travelling to specialist centres
elsewhere [54]. The Spectra Optia system may have the
potential to standardise clinical practice at a national level.
There may be the possibility that these patients could
access Spectra Optia through a specialised care service
such as one of six regional NHS Blood and Transplant
Therapeutic Apheresis Services [55], and therefore it is
possible these inequalities could be addressed through this
or similar mechanisms.
8 Conclusion
Automated RBC exchange using the Spectra Optia system
has been recommended by NICE for elective use in people
with sickle cell disease in MTG 28. There is a lack of
Table 3 Summary of cost-saving potential of Spectra Optia in all scenarios considered by the EAC
Population Option No overloada Mild overload Moderate overload Severe overload
Adults Auto vs.
manual
Generally, Spectra Optia is cost
saving, except where extreme
assumptions are used
Spectra Optia is comfortably
cost saving over manual
Spectra Optia is cost saving
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over manual where the less
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EAC external assessment centre, TUT top-up transfusion
a Overload status refers to the degree of iron overloading present at the beginning of the model. There is no definition of this stratification and it
is not recognised by clinical experts
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prospective comparative evidence of clinical efficacy and
safety on Spectra Optia and currently the economic evi-
dence to support cost savings is not robust. Prospective
comparative research is not expected in the future owing to
a lack of clinical equipoise. However, expert opinion,
supported by limited observational data, is unanimous that
the Spectra Optia system offers the potential to improve
technical efficiency and thereby clinical endpoints, the
most important of which is reducing or preventing iron
overload. A reduced requirement for iron chelation therapy
from automated RBC exchange should result in material
cost savings to the NHS. Additionally, the widespread
adoption of Spectra Optia could reduce current inequalities
concerning the provision of treatment for sickle cell
disease.
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